RM-TRS / Tissue, repair and matrix signalling
Cibinetide
Also known as: ARA-290 · Helix B surface peptide
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Cibinetide is a synthetic peptide derived from the helix B surface of erythropoietin. ARA-290 is an older development name. The exact sequence and preparation matter when comparing records.
Evidence position
Human interventional work supports a Grade B index position. The evidence is early and does not support broad outcome language.
What the record does not establish
Published studies do not authenticate any supplier, vial or lot. They also do not transfer the properties of a controlled investigational formulation to differently sourced material.
Sources
- 01A Phase 2 Clinical Trial on the Use of Cibinetide for Diabetic Macular EdemaPubMed
- Shows
- Small phase 2 human study with eight completers and mixed exploratory findings
- Does not show
- Small sample, one condition and one controlled investigational preparation
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Cibinetide
- CID
- 91810664
- Formula
- C51H84N16O21
- Mass
- 1257.3
PUBMED / FOUND RECORDS
- Editorial.Molecular medicine (Cambridge, Mass.) / 2013 Nov 8PMID 24178588 / DOI 10.2119/molmed.2013.00135
- The time to develop treatments for diabetic neuropathy.Expert opinion on investigational drugs / 2021 FebPMID 33423557 / DOI 10.1080/13543784.2021.1868433
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.Journal of clinical medicine / 2020 Jul 14PMID 32674280 / DOI 10.3390/jcm9072225
- Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.Scientific reports / 2017 Oct 12PMID 29026145 / DOI 10.1038/s41598-017-13046-3
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis.Expert opinion on investigational drugs / 2014 AprPMID 24555851 / DOI 10.1517/13543784.2014.892072
CLINICALTRIALS.GOV / FOUND RECORDS
- The Use of ARA290 for the Treatment of Diabetic Macular OedemaTERMINATED / PHASE2 / Belfast Health and Social Care TrustNCT06626971 / DIRECT intervention MATCH: ARA-290
- ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)UNKNOWN / PHASE2 / Claes-Göran ÖstensonNCT01933529 / DIRECT intervention MATCH: ARA-290
- Cognitive and Neural Effects of ARA290COMPLETED / PHASE1, PHASE2 / Leiden University Medical CenterNCT02070783 / DIRECT intervention MATCH: ARA-290
- Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisCOMPLETED / PHASE2 / Araim Pharmaceuticals, Inc.NCT02039687 / DIRECT intervention MATCH: Cibinetide